Nature：另辟蹊径！通过焦亡膜孔递送药物，阻断细胞焦亡，治疗炎症相关疾病

TL;DR — A Genentech team publishing in Nature (28 July 2026) turned gasdermin D (GSDMD) membrane pores into a drug-entry route, using cell-impermeable covalent caspase inhibitors that only reach cells already undergoing pyroptosis, blocking IL-1β/IL-18 release without touching healthy cells. Note: this is a chemical-biology/therapeutics paper with no AI/ML component.

• Substrate profiling with a hybrid combinatorial library (HyCoSuL) showed human caspase-1/4/5 prefer His at P2, Glu at P3, and bulky aromatic residues at P4; ~100 tetrapeptide inhibitors bearing acyloxymethyl ketone (AOMK) warheads were synthesized for covalent, irreversible binding.
• Three low-permeability leads (KGR-3, KGR-23, KGR-72) selectively suppressed pyroptosis and IL-1β secretion while sparing caspase-driven apoptosis, since non-pyroptotic cells lack pores — avoiding the toxicity that sank cell-permeable pan-caspase inhibitors.
• Because pore formation races ESCRT-mediated membrane repair and proceeds asynchronously, dosing hours after pyroptosis onset still halted further cell death, implying a wide therapeutic window.
• In vivo, KGR-53P (a charge-neutralized P3 variant designed for better pore passage) inhibited caspase-11 and reduced IL-1β/IL-18 in an LPS endotoxic shock mouse model, establishing "pore-mediated delivery" as a general paradigm potentially extensible to sepsis, ARDS, and COVID-19.